Zavante hits the finish line, declaring a pivotal win for its antibiotic now headed (eventually) to the FDA
The team at Zavante Therapeutics had a very simple goal.
Armed with $45 million in investor backing, they took a broad spectrum antibiotic that’s been used in various countries around the world — outside the US — and put it through a late-stage, head-to-head, non-inferiority trial against a combo antibiotic that’s already in use in the US.
And they are claiming a win, prepping an FDA application now for a new antibiotic in an increasingly drug-resistant world as they consider their options: marketing it themselves or selling it to a player in the field.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
